GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference
Topics/Oncology/Fasting Alone Does Not Stabilise Stomach Volume During Pancreatic SBRT: Practical Radiation Oncology | June 2026

Fasting Alone Does Not Stabilise Stomach Volume During Pancreatic SBRT: Practical Radiation Oncology | June 2026

Clinical knowledge base curated and reviewed by GastroAGI TeamLast updated June 1, 2026

Quick Answer

• Pancreatic stereotactic body radiotherapy (SBRT) requires highly precise treatment because the pancreas lies immediately adjacent to radiosensitive organs such as the stomach and duodenum. • Most centres instruct patients to fast before simulation and treatment, assuming that an empty stomach will reduce daily variation and improve treatment reproducibility.


  • Pancreatic stereotactic body radiotherapy (SBRT) requires highly precise treatment because the pancreas lies immediately adjacent to radiosensitive organs such as the stomach and duodenum.
  • Most centres instruct patients to fast before simulation and treatment, assuming that an empty stomach will reduce daily variation and improve treatment reproducibility.
  • This study evaluated whether a standardised 2-hour fasting protocol actually produces consistent stomach volumes during pancreatic SBRT.
  • Seventy-four patients undergoing pancreatic SBRT were analysed with repeated imaging throughout treatment.
  • The results showed that fasting instructions alone were insufficient for many patients.
  • Approximately 58% of patients demonstrated substantial day-to-day stomach volume variability despite following identical fasting instructions.
  • Patients with larger stomach volumes at simulation were more likely to show significant variation during treatment.
  • A baseline stomach volume of approximately >200 cc identified patients at higher risk for inter-fraction variability.
  • Surprisingly, total stomach volume correlated poorly with the volume of stomach located near the treatment target.
  • This finding is clinically important because radiation toxicity depends primarily on the stomach immediately adjacent to the planning target volume rather than the total gastric volume.
  • Simply measuring overall stomach size may therefore be inadequate when assessing radiation risk.
  • The study challenges the common assumption that uniform fasting instructions guarantee reproducible anatomy during pancreatic radiation therapy.
  • Adaptive radiotherapy, image guidance, and individualised preparation strategies may remain necessary despite fasting protocols.
  • Baseline simulation imaging may help identify patients who require more intensive motion management or adaptive planning.
  • The findings are particularly relevant as pancreatic SBRT continues to expand and dose escalation strategies increasingly rely on precise organ-at-risk avoidance.

Bottom line: A standard 2-hour fasting protocol does not reliably produce consistent stomach volumes during pancreatic SBRT. Patients with larger baseline stomach volumes are particularly prone to day-to-day variability, highlighting the need for individualised image-guided and adaptive treatment strategies.

Related Q&A

The First Standardized PET Response Framework for Neuroendocrine Tumors: The Lancet Oncology | July 2026

Introduction: Somatostatin receptor (SSTR) PET/CT has become indispensable for diagnosing, staging, and monitoring neuroendocrine tumors (NETs). However, until now, there has been no standardized method for assessing treatment response using SSTR PET imaging. This international...

Staging Laparoscopy in Gastric Cancer: Annals of Surgical Oncology | July 2026

Introduction: Staging laparoscopy (SL) is recommended for patients with locally advanced gastric cancer to detect occult peritoneal metastases before curative treatment. However, its real-world utilization across Europe remains uncertain. This large GASTRODATA study evaluated the...

Celecoxib Boosts Neoadjuvant Immunotherapy in dMMR/MSI-H CRC : Lancet Oncol | Jul 2026

Introduction: Neoadjuvant immune checkpoint inhibitors have transformed the management of mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) locally advanced colorectal cancer, achieving unprecedented pathological response rates. Experimental evidence suggests that cyclooxygenase-2 (COX-2) inhibition may enhance...

Cancer Cachexia: Science | July 2026

Introduction: Cancer-associated cachexia is a devastating syndrome characterized by loss of appetite, weight loss, and muscle wasting, affecting up to half of patients with lung cancer. This landmark study uncovers a previously unrecognized mechanism linking...

Liquid Biopsy-Guided Cetuximab Rechallenge in mCRC: ESMO GI Cancers Congress | July 2026

Introduction: Resistance to anti-EGFR therapy has traditionally been considered irreversible in metastatic colorectal cancer (mCRC). However, emerging evidence suggests that resistance is dynamic and can be monitored using circulating tumor DNA (ctDNA). The CAPRI-2 trial...

PD-(L)1 Inhibitors Plus Chemotherapy in Advanced Gastric Cancer: CGH | July 2026

Introduction: Immune checkpoint inhibitors combined with chemotherapy have become the standard first-line treatment for advanced HER2-negative gastric and gastroesophageal junction cancers. This meta-analysis evaluated whether treatment benefits differ between Asian and non-Asian populations. Why was...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer